Kim Reiss Binder, Pancreatic cancer researcher at University of Pennsylvania, shared on X:
“Putting out the signal for EA2192 (APOLLO). 97/152 patients enrolled! Patients with BRCA or PALB2 who have completed curative intent tx for PDAC within the last 3 months are eligible.”
More insights from APOLLO Trial.